A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

← catalyst calendar

NCT07155174 · readout ≤ 985 d

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

180estimated

Sites

Countries

Belgium, China, Germany +10

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-11-25

actual

When the study began enrolling

Primary completion

Apr 2029

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Sep 2031

estimated

The whole study's end, after follow-up

First posted

2025-09-04

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-14

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Small Cell Lung Cancer

Interventions

Drug: ABBV-706
Drug: Atezolizumab
Drug: Etoposide
Drug: Carboplatin
Drug: Carboplatin
Drug: Lurbinectedin

Primary outcomes

what the primary-completion date above is the date OF

Number of Participants with Adverse Events (AE)s

measured Up to 69.5 Months

Progression-Free Survival (PFS) Based on Investigator Assessment

measured Up to Approximately 24 Months

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed